FRA:GU5 (China)
Â
Class H
€
1.69
+0.060 (+3.68%)
Jul 6
Business Description
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
ISIN : CNE100000387
Share Class Description:
FRA:GU5: Class HTotal Employee Number:
27,057Compare
Compare
Traded in other countries / regions
600332.China00874.Hong KongGU5.GermanyGZPHF.USA IPO Date
2012-07-04Description
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd is engaged in the pharmaceutical and healthcare industry, focusing on the development of a full industrial chain covering research, manufacturing, and distribution. The group operates through five reportable segments. The Modern Chinese Medicine segment involves the R&D, manufacturing, and sale of proprietary Chinese and natural medicines. The Chemical Pharmaceutical Technology segment focuses on chemical drugs, APIs, and intermediates. The Natural Beverages segment produces and sells health-oriented beverage products. The Pharmaceutical Commerce segment is engaged in the wholesale, retail, and import/export of medicines and medical devices. The Other Segments include biotechnology innovation, consumer health, and medical services.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.67 | |||||
Equity-to-Asset | 0.44 | |||||
Debt-to-Equity | 0.47 | |||||
Debt-to-EBITDA | 4.53 | |||||
Interest Coverage | 8.8 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 2.15 | |||||
Beneish M-Score | -2.38 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 3.1 | |||||
3-Year EBITDA Growth Rate | -7.1 | |||||
3-Year EPS without NRI Growth Rate | -10.7 | |||||
3-Year Book Growth Rate | 5.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 6.13 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 4.9 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 79.71 | |||||
9-Day RSI | 66.93 | |||||
14-Day RSI | 58.77 | |||||
3-1 Month Momentum % | -11.76 | |||||
6-1 Month Momentum % | -17.09 | |||||
12-1 Month Momentum % | -12.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.6 | |||||
Quick Ratio | 1.29 | |||||
Cash Ratio | 0.3 | |||||
Days Inventory | 65.33 | |||||
Days Sales Outstanding | 85.59 | |||||
Days Payable | 97.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 6.23 | |||||
Dividend Payout Ratio | 0.41 | |||||
3-Year Dividend Growth Rate | 5.2 | |||||
Forward Dividend Yield % | 6.23 | |||||
5-Year Yield-on-Cost % | 11.23 | |||||
Shareholder Yield % | -3.22 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 16.22 | |||||
Operating Margin % | 4.52 | |||||
Net Margin % | 3.75 | |||||
EBITDA Margin % | 5.19 | |||||
FCF Margin % | 0.14 | |||||
OCF Margin % | 1.71 | |||||
ROE % | 7.72 | |||||
ROA % | 3.51 | |||||
ROIC % | 6.31 | |||||
3-Year ROIIC % | -7.56 | |||||
ROC (Joel Greenblatt) % | 17.7 | |||||
ROCE % | 8.91 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 12.12 | |||||
Forward PE Ratio | 7.02 | |||||
PE Ratio without NRI | 11.45 | |||||
Shiller PE Ratio | 10.24 | |||||
Price-to-Owner-Earnings | 20.71 | |||||
PS Ratio | 0.46 | |||||
PB Ratio | 0.9 | |||||
Price-to-Tangible-Book | 1.01 | |||||
Price-to-Free-Cash-Flow | 170.31 | |||||
Price-to-Operating-Cash-Flow | 24.69 | |||||
EV-to-EBIT | 10.25 | |||||
EV-to-EBITDA | 10.25 | |||||
EV-to-Revenue | 0.53 | |||||
EV-to-FCF | 196.48 | |||||
Price-to-GF-Value | 0.71 | |||||
Price-to-Projected-FCF | 0.75 | |||||
Price-to-Median-PS-Value | 0.59 | |||||
Price-to-Graham-Number | 0.72 | |||||
| Price-to-Net-Current-Asset-Value | 2.41 | |||||
Earnings Yield (Greenblatt) % | 9.75 | |||||
FCF Yield % | 0.63 | |||||
Forward Rate of Return (Yacktman) % | 0.75 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 9,570.091 | ||
| EPS (TTM) (€) | 0.224 | ||
| Beta | 0.3752 | ||
| 3-Year Sharpe Ratio | -1.02 | ||
| 3-Year Sortino Ratio | -1.17 | ||
| Volatility % | 17.36 | ||
| 14-Day RSI | 58.77 | ||
| 14-Day ATR (€) | 0.025401 | ||
| 20-Day SMA (€) | 1.618 | ||
| 12-1 Month Momentum % | -12.23 | ||
| 52-Week Range (€) | 1.55 - 2.3 | ||
| Shares Outstanding (Mil) | 1,625.79 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| HKD 0.516200 Cash Dividend | 2026-06-12 | 1.67 (+0.00%) | ||
| HKD 0.439900 Cash Dividend | 2025-08-29 | 1.99 (+1.02%) | ||
| HKD 0.436200 Cash Dividend | 2025-06-16 | 1.96 (+0.00%) | ||
| HKD 0.442200 Cash Dividend | 2024-10-15 | 2.22 (+0.00%) |
Show
Entries
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Frequently Asked Questions
What is Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd(FRA:GU5)'s stock price today?
The current price of FRA:GU5 is €1.69. The 52 week high of FRA:GU5 is €2.30 and 52 week low is €1.55.
When is next earnings date of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd(FRA:GU5)?
The next earnings date of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd(FRA:GU5) is .
Does Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd(FRA:GU5) pay dividends? If so, how much?
The Dividend Yield %  of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd(FRA:GU5) is 6.23% (As of Today), Highest Dividend Payout Ratio of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd(FRA:GU5) was 0.79. The lowest was 0.24. And the median was 0.33. The  Forward Dividend Yield % of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd(FRA:GU5) is 6.23%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers